On March 31, 2026, INNOVATE Corp. (NYSE: VATE) announced that its equity method investment, MediBeacon Inc., has received the European Union (EU) CE Mark certification for its TGFR™ Monitor and TGFR™ Reusable Sensor. This certification signifies that the devices meet the stringent safety, quality, and performance standards set by the EU Medical Device Regulation (MDR) 2017/745. The CE Mark is a significant milestone for MediBeacon, allowing the TGFR™ System to be utilized in clinical trials across European sites as it enters the clinic in the U.S. and China. Steven Hanley, CEO and Co-Founder of MediBeacon, emphasized the importance of this achievement, stating that it underscores their commitment to high-quality and safety standards. The TGFR™ System, which includes the Monitor and Sensor, enables the assessment of kidney function through a non-invasive method by measuring the clearance rate of a fluorescent agent. This innovative approach could revolutionize kidney function assessment and improve patient outcomes in clinical settings. MediBeacon's technology is already approved for human use by the U.S. FDA and the China NMPA, with further submissions pending in the EU. The announcement is expected to have a positive impact on INNOVATE's stock price as it highlights the company's advancements in medical technology and potential for growth in the healthcare sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.